Adjuvant systemic therapy in breast cancer: quo vadis?

Understanding and managing breast cancer: quo vadis?

Recent advances in adjuvant systemic therapy for early-stage breast cancer.

More than 429 000 European women are diagnosed with breast cancer annually [1]. The vast majority of women present with early-stage disease and receive adjuvant systemic therapy following surgical resection. Although rates of breast cancerrelated mortality have continued to decline in Europe since the early 1990s, many women diagnosed with early-stage breast cancer will die due to disease recur...

The new millennium for adjuvant therapy in breast cancer.

The treatment of microscopic metastatic breast cancer with adjuvant systemic therapy has undergone significant changes in recent years. At the same time, our understanding of the biology of breast cancer has also improved, predominantly as a consequence of data obtained from cDNA microarrays. Breast cancer genomic analyses now suggest that current breast cancer systemic therapies have a profoun...

Progress in adjuvant chemotherapy for breast cancer: an overview

Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the risk of distant and local recurrence, including endocrine therapy, a...

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer

BACKGROUND The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients are managed in clinical practice in Italy, which clinical or biological characteristics influenced the choice of adjuvant systemic therapy...